Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force.

Etan OrgelThomas B AlexanderBrent L WoodSamir B KahwashMeenakshi DevidasYunfeng DaiTodd A AlonzoCharles G MullighanHiroto InabaStephen P HungerElizabeth A RaetzAlan S GamisKaren R RabinAndrew J CarrollNyla A HeeremaJason N BermanWilliam G WoodsMignon L LohPatrick A Zweidler-McKayJohn T Horannull null

Published in: Cancer (2019)

The results of the COG MPAL cohort and a literature review suggest that ALL chemotherapy without HSCT may be the preferred initial therapy. A prospective trial within the COG is proposed to investigate this approach; AML chemotherapy and/or HSCT will be reserved for those with treatment failure as assessed by minimal residual disease. Embedded biology studies will provide further insight into MPAL genomics.

Keyphrases

locally advanced
single cell
hematopoietic stem cell
acute myeloid leukemia
study protocol
case report
phase iii
randomized controlled trial
stem cells
combination therapy
clinical practice
case control
allogeneic hematopoietic stem cell transplantation
cell therapy
mesenchymal stem cells
open label